BTG2 and neoplasm: miR-25 is upregulated in both tumor and serum of radioresistant patients than in radiosensitive ones, whereas the putative target of the miRNA, BTG2, an antiproliferative gene, is downregulated, affecting sensitivity to radiotherapy